Survival analyses from the ZEBRA study. goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer.

Kaufmann M, Jonat W, Blamey R, Cuzick J, Namer M, Fogelman I, de Haes JC, Schumacher M, Sauerbrei W

European journal of cancer (Oxford, England : 1990)1 Aug 2003Cited by 72 (Europe PMC)

PMID12888366DOI10.1016/s0959-8049(03)00392-7PepBankPUB-12888366

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanNon-randomized trialEfficacy outcome
In women with ER-positive, node-positive early breast cancer, goserelin was non-inferior to CMF for overall survival.
In plain wordsIn women with ER-positive breast cancer, goserelin was non-inferior to CMF chemotherapy for overall survival.
Peptide
Goserelin
Outcome
Not applicableOverall survival in ER-positive disease
Study
n: not reported in source
Comparator
CMF chemotherapy
Outcome group
Cancer biomarkers and prognosis · Cancer
Studied dose
Dose not stated
Source sentences
Summary
In patients with oestrogen receptor (ER)-positive tumours, non-inferiority of goserelin versus CMF for OS was shown; goserelin was again shown to be equivalent to CMF for DFS.
2 context sentences(design, population, supporting numbers)
Summary · context
The Zoladex Early Breast Cancer Research Association (ZEBRA) trial compared the efficacy and tolerability of goserelin (Zoladex) with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy in pre-/perimenopausal women with node-positive early breast cancer.
Summary · context
Here we present an update including data on overall survival (OS) from the ZEBRA trial at a median follow-up of 7.3 years.
Report a problemFND-1288836601
02HumanNon-randomized trialEfficacy outcome
In women with ER-positive, node-positive early breast cancer, goserelin and CMF were equivalent for disease-free survival.
In plain wordsIn women with ER-positive breast cancer, disease-free survival was equivalent with goserelin and CMF chemotherapy.
Peptide
Goserelin
Outcome
No significant changeDisease-free survival in ER-positive disease
Study
n: not reported in source
Comparator
CMF chemotherapy
Outcome group
Cancer biomarkers and prognosis · Cancer
Studied dose
Dose not stated
Source sentences
Summary
In patients with oestrogen receptor (ER)-positive tumours, non-inferiority of goserelin versus CMF for OS was shown; goserelin was again shown to be equivalent to CMF for DFS.
2 context sentences(design, population, supporting numbers)
Summary · context
The Zoladex Early Breast Cancer Research Association (ZEBRA) trial compared the efficacy and tolerability of goserelin (Zoladex) with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy in pre-/perimenopausal women with node-positive early breast cancer.
Summary · context
Here we present an update including data on overall survival (OS) from the ZEBRA trial at a median follow-up of 7.3 years.
Report a problemFND-1288836602
03HumanNon-randomized trialEfficacy outcome
In women with ER-positive, node-positive early breast cancer, goserelin and CMF were equivalent for distant disease-free survival.
In plain wordsIn women with ER-positive breast cancer, distant disease-free survival was equivalent with goserelin and CMF chemotherapy.
Peptide
Goserelin
Outcome
No significant changeDistant disease-free survival in ER-positive disease
Study
n: not reported in source
Comparator
CMF chemotherapy
Outcome group
Cancer biomarkers and prognosis · Cancer
Studied dose
Dose not stated
Source sentences
Summary
This updated analysis has demonstrated that the two treatments are also equivalent for distant disease-free survival (DDFS).
3 context sentences(design, population, supporting numbers)
Summary · context
In patients with oestrogen receptor (ER)-positive tumours, non-inferiority of goserelin versus CMF for OS was shown; goserelin was again shown to be equivalent to CMF for DFS.
Summary · context
The Zoladex Early Breast Cancer Research Association (ZEBRA) trial compared the efficacy and tolerability of goserelin (Zoladex) with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy in pre-/perimenopausal women with node-positive early breast cancer.
Summary · context
Here we present an update including data on overall survival (OS) from the ZEBRA trial at a median follow-up of 7.3 years.
Report a problemFND-1288836603
04HumanNon-randomized trialEfficacy outcome
In women with ER-negative, node-positive early breast cancer, goserelin was inferior to CMF for disease-free survival.
In plain wordsIn women with ER-negative breast cancer, disease-free survival was worse with goserelin than CMF chemotherapy.
Peptide
Goserelin
Outcome
DecreaseDisease-free survival in ER-negative disease
Study
n: not reported in source
Comparator
CMF chemotherapy
Outcome group
Cancer biomarkers and prognosis · Cancer
Studied dose
Dose not stated
Source sentences
Summary
In patients with ER-negative disease, goserelin was inferior to CMF for DFS, DDFS and OS.
2 context sentences(design, population, supporting numbers)
Summary · context
The Zoladex Early Breast Cancer Research Association (ZEBRA) trial compared the efficacy and tolerability of goserelin (Zoladex) with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy in pre-/perimenopausal women with node-positive early breast cancer.
Summary · context
Here we present an update including data on overall survival (OS) from the ZEBRA trial at a median follow-up of 7.3 years.
Report a problemFND-1288836604
05HumanNon-randomized trialEfficacy outcome
In women with ER-negative, node-positive early breast cancer, goserelin was inferior to CMF for distant disease-free survival.
In plain wordsIn women with ER-negative breast cancer, distant disease-free survival was worse with goserelin than CMF chemotherapy.
Peptide
Goserelin
Outcome
DecreaseDistant disease-free survival in ER-negative disease
Study
n: not reported in source
Comparator
CMF chemotherapy
Outcome group
Cancer biomarkers and prognosis · Cancer
Studied dose
Dose not stated
Source sentences
Summary
In patients with ER-negative disease, goserelin was inferior to CMF for DFS, DDFS and OS.
2 context sentences(design, population, supporting numbers)
Summary · context
The Zoladex Early Breast Cancer Research Association (ZEBRA) trial compared the efficacy and tolerability of goserelin (Zoladex) with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy in pre-/perimenopausal women with node-positive early breast cancer.
Summary · context
Here we present an update including data on overall survival (OS) from the ZEBRA trial at a median follow-up of 7.3 years.
Report a problemFND-1288836605
06HumanNon-randomized trialEfficacy outcome
In women with ER-negative, node-positive early breast cancer, goserelin was inferior to CMF for overall survival.
In plain wordsIn women with ER-negative breast cancer, overall survival was worse with goserelin than CMF chemotherapy.
Peptide
Goserelin
Outcome
DecreaseOverall survival in ER-negative disease
Study
n: not reported in source
Comparator
CMF chemotherapy
Outcome group
Cancer biomarkers and prognosis · Cancer
Studied dose
Dose not stated
Source sentences
Summary
In patients with ER-negative disease, goserelin was inferior to CMF for DFS, DDFS and OS.
2 context sentences(design, population, supporting numbers)
Summary · context
The Zoladex Early Breast Cancer Research Association (ZEBRA) trial compared the efficacy and tolerability of goserelin (Zoladex) with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy in pre-/perimenopausal women with node-positive early breast cancer.
Summary · context
Here we present an update including data on overall survival (OS) from the ZEBRA trial at a median follow-up of 7.3 years.
Report a problemFND-1288836606

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT02518191

Effects of GnRHa on Ovarian Function Against Chemotherapy-induced-gonadotoxicity

Xiangyun Zongn = 3451 Sept 2015 to 12 Jan 2021

Breast Cancer

Trial page ClinicalTrials.govUpdated 11 Jun 2021

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.